Hologic, Inc. logo
Hologic, Inc. (HOLX)
Compare

Hologic, Inc. (HOLX) PS Ratio: 4.16

Is Hologic, Inc.’s P/S ratio high or low?

Hologic, Inc.'s P/S ratio of 4.16 is in line with its 5-year average of 3.99, around the middle of its 5-year range (2.95–5.18).

As of Thursday, June 11, 2026. 8.65% above its 12-month average of 3.83.

HOLX PS Ratio Chart

HOLX PS Ratio
4.16+18.18% 1Y
Zoom

HOLX Average PS Ratio Chart

HOLX Current vs Average PS Ratio Chart

HOLX PS Ratio Metrics

PS RATIO

4.16

PS RATIO AVG TTM

3.83

PS RATIO AVG 3Y

4.27

PS RATIO AVG 5Y

3.99

PS RATIO AVG 10Y

3.99

PS RATIO AVG 15Y

3.66

PS RATIO AVG 20Y

3.72

CURRENT VS TTM AVG

+8.65%

CURRENT VS 3Y AVG

-2.66%

CURRENT VS 5Y AVG

+4.39%

CURRENT VS 10Y AVG

+4.30%

CURRENT VS 15Y AVG

+13.70%

CURRENT VS 20Y AVG

+11.79%

HOLX Competitors' PS Ratio

NAMEMARKET CAPPS RATIOTTM3Y5Y
Hologic, Inc. (HOLX)$16.97B4.163.834.273.99
Moderna, Inc. (MRNA)$18.71B8.386.125.207.09
Align Technology, Inc. (ALGN)$12.27B2.992.944.296.14
BioNTech SE (BNTX)$22.39B6.637.566.755.47
Mettler-Toledo International Inc. (MTD)$22.82B5.606.806.977.67
Waters Corporation (WAT)$23.21B7.916.606.586.83
Baxter International Inc. (BAX)$10.58B0.931.001.301.80
Charles River Laboratories International, Inc. (CRL)$8.94B2.262.132.363.07
Bio-Rad Laboratories, Inc. (BIO)$7.92B3.073.033.314.32
Veeva Systems Inc. (VEEV)$26.31B8.1913.0513.7616.18

P/S vs. its own history

At 4.16, P/S is richer than usual, sitting higher than 69% of its 20-year history.

20-year low

1.40

median

3.65

20-year high

8.26

cheaperricher

Sales Valuation

P/S Ratio

4.16

Market Cap / Annual Revenue

Hologic, Inc. PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Hologic, Inc. PS Ratio FAQ

What is the P/S ratio for Hologic, Inc. (HOLX)?
The P/S ratio for HOLX stock is 4.16.
Is Hologic, Inc.'s P/S ratio high or low?
Hologic, Inc.'s P/S ratio of 4.16 is in line with its 5-year average of 3.99, around the middle of its 5-year range (2.95–5.18).
What is the TTM average P/S ratio for Hologic, Inc. (HOLX)?
The TTM average P/S ratio for HOLX stock is 3.83.
What is the 3Y average P/S ratio for Hologic, Inc. (HOLX)?
The 3Y average P/S ratio for HOLX stock is 4.27.
What is the 5Y average P/S ratio for Hologic, Inc. (HOLX)?
The 5Y average P/S ratio for HOLX stock is 3.99.
What is the 10Y average P/S ratio for Hologic, Inc. (HOLX)?
The 10Y average P/S ratio for HOLX stock is 3.99.
What is the 15Y average P/S ratio for Hologic, Inc. (HOLX)?
The 15Y average P/S ratio for HOLX stock is 3.66.
What is the 20Y average P/S ratio for Hologic, Inc. (HOLX)?
The 20Y average P/S ratio for HOLX stock is 3.72.

Hologic, Inc. PS Ratio History

DATEPS RATIO
2026-04-074.16
2026-04-064.16
2026-04-024.14
2026-04-014.14
2026-03-314.14
2026-03-304.14
2026-03-274.14
2026-03-264.14
2026-03-254.13
2026-03-244.14
2026-03-234.14
2026-03-204.13
2026-03-194.12
2026-03-184.11
2026-03-174.11
2026-03-164.11
2026-03-134.11
2026-03-124.12
2026-03-114.13
2026-03-104.14
2026-03-094.14
2026-03-064.15
2026-03-054.15
2026-03-044.14
2026-03-034.13
2026-03-024.13
2026-02-274.13
2026-02-264.12
2026-02-254.12
2026-02-244.12
2026-02-234.13
2026-02-204.13
2026-02-194.11
2026-02-184.12
2026-02-174.11
2026-02-134.11
2026-02-124.10
2026-02-114.11
2026-02-104.11
2026-02-094.11
2026-02-064.10
2026-02-054.09
2026-02-044.08
2026-02-034.09
2026-02-024.09
2026-01-304.10
2026-01-294.10
2026-01-284.13
2026-01-274.14
2026-01-264.14
2026-01-234.13
2026-01-224.13
2026-01-214.14
2026-01-204.13
2026-01-164.13
2026-01-154.13
2026-01-144.14
2026-01-134.12
2026-01-124.12
2026-01-094.12
2026-01-084.12
2026-01-074.13
2026-01-064.12
2026-01-054.12
2026-01-024.10
2025-12-314.10
2025-12-304.10
2025-12-294.10
2025-12-264.10
2025-12-244.10
2025-12-234.12
2025-12-224.12
2025-12-194.13
2025-12-184.13
2025-12-174.12
2025-12-164.13
2025-12-154.14
2025-12-124.13
2025-12-114.12
2025-12-104.12
2025-12-094.12
2025-12-084.12
2025-12-054.13
2025-12-044.12
2025-12-034.13
2025-12-024.12
2025-12-014.12
2025-11-284.13
2025-11-264.12
2025-11-254.12
2025-11-244.12
2025-11-214.09
2025-11-204.08
2025-11-194.08
2025-11-184.08
2025-11-174.14
2025-11-144.14
2025-11-134.15
2025-11-124.16
2025-11-114.16
2025-11-104.15
2025-11-074.14
2025-11-064.14
2025-11-054.14
2025-11-044.14
2025-11-034.13
2025-10-314.13
2025-10-304.13
2025-10-294.13
2025-10-284.13
2025-10-274.13
2025-10-244.13
2025-10-234.12
2025-10-224.13
2025-10-214.13
2025-10-204.01
2025-10-173.90
2025-10-163.82
2025-10-153.74
2025-10-143.68
2025-10-133.66
2025-10-103.78
2025-10-093.83
2025-10-083.81
2025-10-073.78
2025-10-063.76
2025-10-033.81
2025-10-023.79
2025-10-013.74
2025-09-303.77
2025-09-293.75
2025-09-263.75
2025-09-253.67
2025-09-243.71
2025-09-233.78
2025-09-223.76
2025-09-193.70
2025-09-183.81
2025-09-173.81
2025-09-163.54
2025-09-153.56
2025-09-123.60
2025-09-113.71
2025-09-103.66
2025-09-093.72
2025-09-083.71
2025-09-053.73
2025-09-043.71
2025-09-033.70
2025-09-023.72
2025-08-293.75
2025-08-283.72
2025-08-273.73
2025-08-263.72
2025-08-253.75
2025-08-223.81
2025-08-213.75
2025-08-203.84
2025-08-193.79
2025-08-183.76
2025-08-153.79
2025-08-143.80
2025-08-133.85
2025-08-123.79
2025-08-113.80
2025-08-083.80
2025-08-073.79
2025-08-063.73
2025-08-053.79
2025-08-043.79
2025-08-013.75
2025-07-313.73
2025-07-303.64
2025-07-293.70
2025-07-283.68
2025-07-253.73
2025-07-243.71
2025-07-233.70
2025-07-223.67
2025-07-213.57
2025-07-183.59
2025-07-173.59
2025-07-163.58
2025-07-153.55
2025-07-143.62
2025-07-113.69
2025-07-103.75
2025-07-093.69
2025-07-083.64
2025-07-073.61
2025-07-033.63
2025-07-023.66
2025-07-013.66
2025-06-303.65
2025-06-273.65
2025-06-263.65
2025-06-253.60
2025-06-243.64
2025-06-233.61
2025-06-203.62
2025-06-183.59
2025-06-173.60
2025-06-163.65
2025-06-133.63
2025-06-123.66
2025-06-113.62
2025-06-103.65
2025-06-093.62
2025-06-063.61
2025-06-053.54
2025-06-043.51
2025-06-033.53
2025-06-023.48
2025-05-303.49
2025-05-293.53
2025-05-283.57
2025-05-273.49
2025-05-233.04
2025-05-223.05
2025-05-213.07
2025-05-203.17
2025-05-193.16
2025-05-163.18
2025-05-153.13
2025-05-143.10
2025-05-133.20
2025-05-123.30
2025-05-093.18
2025-05-083.15
2025-05-073.11
2025-05-062.98
2025-05-052.96
2025-05-023.04
2025-05-013.29
2025-04-303.34
2025-04-293.35
2025-04-283.34
2025-04-253.33
2025-04-243.35
2025-04-233.34
2025-04-223.34
2025-04-213.27
2025-04-173.31
2025-04-163.25
2025-04-153.33
2025-04-143.38
2025-04-113.32
2025-04-103.28
2025-04-093.41
2025-04-083.36
2025-04-073.52
2025-04-043.50
2025-04-033.55
2025-04-023.48
2025-04-013.53
2025-03-313.55
2025-03-283.52
2025-03-273.58
2025-03-263.53
2025-03-253.49

Showing the most recent 260 of 5,030 data points. The chart above shows the full history.

About Hologic, Inc.

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA
7,063 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Paul Malenchini